1 March 2022
The lack of appropriate paediatric medicines and formulations is hindering the achievement of the Sustainable Development Goals and universal health coverage and is putting children’s lives at risk.
The Global Accelerator for Paediatric Formulations Strategy (GAP-f) 2022–2024 strategy builds from the work undertaken to date by the network of leading partners, both individually and collectively, through GAP-f. With this new strategy, we are excited to increase our footprint into a broader set of diseases to bring us closer to our vision of all children having equitable access to the medicines they need.
Access the strategy
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.